Tourmaline Bio, Inc.
TRMLDelisted Oct 28, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001827506
Tourmaline Bio, Inc. was delisted on Oct 28, 2025; its insiders filed their last Form 4 on Oct 28, 2025; 134 institutions reported holding it in 13F filings for Q3 2025, worth $1.03B in total; no superinvestor held it.
Q1 2025 vs. Q4 2024
How the institutions holding Tourmaline Bio, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Of which not filed for Q1 2025 | Q1 2025 | Change |
|---|---|---|---|---|
| Holders | 101 | 1 | 107 | +7 |
| Shares | 22.9M | 76.2K | 23.9M | +1.16M (+5.1%) |
| Value | $463.6M | $1.55M | $364.3M | −$97.8M (−21.2%) |
1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (19)
Institutions that held Tourmaline Bio, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Octagon Capital Advisors LP | 905,000 | $13.8M | 2.99% |
| Balyasny Asset Management LLC | 592,975 | $9.02M | 0.02% |
| Nuveen, LLC | 77,607 | $1.18M | 0.00% |
| EntryPoint Capital, LLC | 24,972 | $379.8K | 0.17% |
| Jump Financial, LLC | 20,893 | $317.8K | 0.00% |
| UBS Oconnor LLC | 17,860 | $271.7K | 0.01% |
| Caption Management, LLC | 14,312 | $217.7K | 0.01% |
| Franklin Resources Inc | 13,892 | $211.3K | 0.00% |
| Two Sigma Advisers, LP | 12,219 | $185.9K | 0.00% |
| HSBC Holdings PLC | 10,357 | $158.4K | 0.00% |
| Price T Rowe Associates Inc | 10,243 | $156.0K | 0.00% |
| BBR Partners, LLC | 10,000 | $152.1K | 0.01% |
| Virtus Investment Advisers, Inc. | 7,289 | $110.9K | 0.03% |
| Farther Finance Advisors, LLC | 1,659 | $23.6K | 0.00% |
| Versant Capital Management, Inc | 600 | $9.13K | 0.00% |
| Caitong International Asset Management Co., Ltd | 121 | $1.84K | 0.00% |
| Jones Financial Companies LLLP | 100 | $1.67K | 0.00% |
| Coldstream Capital Management Inc | 43 | $655 | 0.00% |
| True Wealth Design, LLC | 18 | $274 | 0.00% |
Sold out (12)
Institutions that held Tourmaline Bio, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| RTW Investments, LP | 736,681 | $14.9M |
| StemPoint Capital LP | 126,400 | $2.56M |
| Prudential Financial Inc | 72,335 | $1.47M |
| Rafferty Asset Management, LLC | 29,844 | $605.2K |
| Jane Street Group, LLC | 17,887 | $362.7K |
| Bridgeway Capital Management, LLC | 15,267 | $309.6K |
| Gsa Capital Partners LLP | 10,198 | $207.0K |
| Qube Research & Technologies Ltd | 9,903 | $200.8K |
| Virtus ETF Advisers LLC | 3,157 | $64.0K |
| Creative Planning | 109 | $2.21K |
| Lindbrook Capital, LLC | 56 | $1.14K |
| SRS Capital Advisors, Inc. | 30 | $609 |
Not filed for Q1 2025 yet (1)
Institutions that held Tourmaline Bio, Inc. at the end of Q4 2024 and haven't filed a 13F for Q1 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Nuveen Asset Management, LLC | 76,245 | $1.55M |